Participated · Seed · Jul 2026

Arkenstone Defense provides a managed operating system that packages government contracting requirements—cleared workforce, payroll and benefits, personnel and facility security, compliance, and accreditation—into a single service for commercial technology companies. The platform is anchored by a Professional Employer Organization (PEO) that legally employs cleared workers and carries the layered functions companies need to win and deliver federal contracts. Arkenstone launched from stealth and is led by co-founder and CEO Peter Dixon and co-founder and COO William Treseder. The company reported that more than two dozen defense technology firms already use its platform. Arkenstone positions itself to reduce the operational lead time and cost of certifications like CMMC Level 2 and other accreditation lifecycles that previously forced startups to build separate government back offices. It is headquartered in Menlo Park, California, with additional offices in Albuquerque, New Mexico and Burr Ridge, Illinois.

Led · Series A · Apr 2026

ONTO Health operates a physician-led platform that integrates fertility care with AI-driven diagnostics, clinical automation, and longevity science. The company positions reproductive care as part of a lifelong health journey rather than a single episode of treatment. It was co-founded by healthcare investor ARTIS alongside CEO Roohi Jeelani, MD, a double board-certified reproductive endocrinology and infertility specialist. Financially, ONTO has just completed a $20 million Series A led by ARTIS and Humania. The company plans to use the funds to expand clinical operations in the U.S. and to enter the Gulf Cooperation Council region. Humania’s participation facilitates the GCC expansion through ties to Makarem S. Batterjee and the Saudi German Group’s hospital and outpatient network.

Participated · Series B · Mar 2026

Unnatural Products has built an integrated discovery platform to engineer synthetic macrocyclic peptides at scale, combining computational design, automated chemistry, and high-throughput biological testing. The company positions macrocyclic peptides as a modality that can marry biologics-level selectivity with small-molecule delivery properties, including potential oral delivery and cell permeability. Its pipeline targets cardiometabolic, inflammatory, and immunological diseases, and the company is advancing lead programs toward clinical development. Unnatural Products has established collaborations with pharma and biotech partners including Novartis, Merck, BridgeBio and argenx; the Novartis deal includes up to $100 million upfront and up to $1.7 billion in milestones. The recent $45 million Series B will fund further platform development and pipeline advancement. The company is headquartered in Santa Cruz, California.

Led · Series A · Jan 2026

Founded in 2018 by Aaron Hannon, Dr. Barbara Oliveira and Professor Martin O’Halloran, Luminate builds an ecosystem that lets cancer patients receive treatment at home rather than in hospital settings. Its first two devices, Lilac and Lily, are designed to mitigate common chemotherapy side effects—peripheral neuropathy and hair loss—and are currently in multi-center clinical trials across the US and Europe, with commercial launch targeted for 2027. The company plans to open access to home cancer care at 40 partner oncology clinics and introduce a patient-led home infusion technology by mid-2026. Clinical data from its neuropathy prevention study are expected in mid-2026, which will inform regulatory and market rollout. Luminate operates from Galway with additional offices in Chicago, San Antonio and Omaha. Including the latest raise, the startup has secured $50 million in funding to date, supporting product development, clinical validation and commercial expansion.

Participated · Series B · Oct 2025

Cartography Biosciences develops antibody-based cancer therapies by integrating large-scale single-cell datasets with computational biology through its ATLAS and SUMMIT discovery platforms. The company aggregates petabyte-scale proprietary data from healthy tissues and tumor profiles and applies machine learning and AI to identify tumor-restricted antigens and antigen combinations. Its platform supports the design of logic-gated and highly selective antibody therapeutics aimed at improving specificity and therapeutic index. Cartography is advancing a pipeline of oncology programs with its lead candidate, CBI-1214, a T-cell engager for colorectal cancer that entered clinical testing in early 2026 and is currently enrolling patients in a Phase 1 trial. The company stated that the strategic investment from Samsung Ventures will help accelerate its oncology programs and expand its drug discovery capabilities.